Humanigen, Inc. (Nasdaq: HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate, lenzilumab, announced that results from the lenzilumab Phase 3 study in hospitalized COVID-19 patients (referred to as ‘LIVE-AIR’) were published online at link.
https://finance.yahoo.com/news/humanigen-announces-publication-results-phase-155300197.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.